Gastric cancer is a global health concern, ranking fifth in cancer diagnoses and fourth in cancer-related deaths worldwide. Despite recent advancements in diagnosis, most cases are detected at advanced stages, resulting in poor outcomes. However, recent breakthroughs in genome analysis have identified biomarkers that hold positive clinical significance for GC treatment. These biomarkers and classifications offer the potential for more precise diagnostic and therapeutic approaches for GC patients. In this review, we explore the classification and molecular pathways in this disease, highlighting potential biomarkers that have emerged in recent studies including targeted therapies and immunotherapies. These advancements provide a promising direction for improving the management of GC.
胃癌是全球性的健康问题，在世界范围内其诊断率位居癌症第五位，死亡率高居第四。尽管近年来诊断技术有所进步，但大多数病例仍在中晚期才被发现，导致预后不佳。然而，基因组分析的最新突破已识别出对胃癌治疗具有积极临床意义的生物标志物。这些生物标志物及分类体系为胃癌患者提供了更精准诊断和治疗方法的可能性。本综述探讨了该疾病的分类及分子通路，重点介绍了近期研究中涌现的潜在生物标志物，包括靶向治疗和免疫治疗相关标志物。这些进展为改善胃癌治疗管理提供了充满希望的方向。
肿瘤(癌症)患者之家